 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...252253254255256257258259260261262...266267» |
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: NRG-GY003: Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jul 15, 2015
P2, N=96, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Yervoy (ipilimumab) / Ono Pharma, BMS
New P2 trial: Cytokine-induced Killer Study for Patients With Stage II Melanoma (clinicaltrials.gov) - Jul 15, 2015
P2, N=300, Not yet recruiting, Sponsor: The First People's Hospital of Changzhou
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Monotherapy: CheckMate 032: A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 9, 2015
P1/2, N=410, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2016 --> Aug 2017
- Yervoy (ipilimumab) / BMS
Trial primary completion date: Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (clinicaltrials.gov) - Jul 9, 2015
P2, N=44, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2016 --> Aug 2017 Trial primary completion date: Jul 2015 --> Nov 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (clinicaltrials.gov) - Jul 9, 2015
P1, N=175, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jul 2015 --> Nov 2015 Trial primary completion date: Jun 2015 --> Oct 2015
- Yervoy (ipilimumab) / BMS
New trial, Metastases: PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=2500, Recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Enrollment change, Trial primary completion date: A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma (clinicaltrials.gov) - Jul 9, 2015
P1, N=12, Completed, Sponsor: University of Utah
Trial primary completion date: Jun 2015 --> Oct 2015 Active, not recruiting --> Completed | N=18 --> 12 | Trial primary completion date: Sep 2015 --> Aug 2014
- Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial primary completion date, Metastases: Doxycycline, Temozolomide and Ipilimumab in Melanoma (clinicaltrials.gov) - Jul 9, 2015
P1/2, N=12, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | N=18 --> 12 | Trial primary completion date: Sep 2015 --> Aug 2014 Active, not recruiting --> Completed | N=58 --> 12 | Trial primary completion date: Nov 2016 --> Jul 2015
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Trial initiation date: YERVOY (clinicaltrials.gov) - Jul 8, 2015
P=N/A, N=158, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=58 --> 12 | Trial primary completion date: Nov 2016 --> Jul 2015 Not yet recruiting --> Active, not recruiting | Initiation date: Jun 2015 --> Mar 2015
- Yervoy (ipilimumab) / BMS
Trial primary completion date, IO biomarker: Neoadjuvant Ipilimumab in Prostate Cancer (clinicaltrials.gov) - Jul 6, 2015
P2a, N=20, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Active, not recruiting | Initiation date: Jun 2015 --> Mar 2015 Trial primary completion date: Sep 2015 --> Sep 2016
- ||||| Opdivo (nivolumab) / BMS
New P1/2 trial, Monotherapy: CheckMate 358: An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (clinicaltrials.gov) - Jul 2, 2015
P1/2, N=200, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| Skyclarys (omaveloxolone) / Biogen
Enrollment change: RTA 408 Capsules in Patients With Melanoma - REVEAL (clinicaltrials.gov) - Jun 30, 2015
P1/2, N=84, Recruiting, Sponsor: Reata Pharmaceuticals, Inc.
Trial primary completion date: Sep 2015 --> Sep 2016 N=54 --> 84
- ||| Xpovio (selinexor) / Karyopharm
Enrollment open, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jun 29, 2015
P1, N=251, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=54 --> 84 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy, Metastases: Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma (clinicaltrials.gov) - Jun 25, 2015
P2, N=30, Active, not recruiting, Sponsor: Jewish General Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Sep 2016
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial: CheckMate 227: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 23, 2015
P3, N=1980, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Jun 23, 2015
P2, N=46, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2014 --> Sep 2016 Active, not recruiting --> Completed
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change: YERVOY (clinicaltrials.gov) - Jun 22, 2015
P=N/A, N=158, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=400 --> 158
- Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, Surgery, Metastases: Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jun 17, 2015
P2, N=112, Recruiting, Sponsor: Academic and Community Cancer Research United
N=400 --> 158 N=176 --> 112 | Trial primary completion date: Dec 2015 --> Dec 2016
- || Firmagon (degarelix) / Astellas, Ferring, Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (clinicaltrials.gov) - Jun 11, 2015
P2, N=53, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=176 --> 112 | Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Tumor-infiltrating lymphocyte, Surgery, Pre-surgery: TOP1201 IPI: Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 11, 2015
P2, N=30, Recruiting, Sponsor: Duke University
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: May 2015 --> Nov 2017
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, Metastases: Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=12, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2015 --> Nov 2017 Trial primary completion date: Mar 2015 --> Mar 2016
- Ontak (denileukin diftitox) / Eisai, TSD Japan, Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment change, Trial termination, Trial primary completion date, Metastases: Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox (clinicaltrials.gov) - Jun 11, 2015
P2, N=2, Terminated, Sponsor: James Graham Brown Cancer Center
Trial primary completion date: Mar 2015 --> Mar 2016 N=42 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Oct 2014; low enrollment r/t requirement of prior treatment with denileukin diftitox
- | Yervoy (ipilimumab) / BMS
Enrollment change, Metastases: Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=21, Completed, Sponsor: Bristol-Myers Squibb
N=42 --> 2 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Oct 2014; low enrollment r/t requirement of prior treatment with denileukin diftitox N=15 --> 21
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
N=15 --> 21 Not yet recruiting --> Recruiting
- ||||| napabucasin (BBI608) / Sumitomo Pharma
New P1/2 trial, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers (clinicaltrials.gov) - Jun 10, 2015
P1/2, N=120, Not yet recruiting, Sponsor: Boston Biomedical, Inc
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, PD(L)-1 Biomarker, IO biomarker: CheckMate 040: An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (clinicaltrials.gov) - Jun 4, 2015
P1, N=270, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting N=405 --> 270
- ||| Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (clinicaltrials.gov) - Jun 4, 2015
P2, N=200, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=405 --> 270 Recruiting --> Active, not recruiting
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Phase classification, Enrollment change, PD(L)-1 Biomarker: Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - May 29, 2015
P2, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Phase classification: P1/2 --> P2 | N=141 --> 52
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov) - May 28, 2015
P2, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1/2 --> P2 | N=141 --> 52 Not yet recruiting --> Recruiting
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, PD(L)-1 Biomarker, IO biomarker: ETCTN-9844: Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (clinicaltrials.gov) - May 26, 2015
P1, N=39, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Oncophage (Heat Shock Protein Peptide Complex-96) / Agenus, Yervoy (ipilimumab) / Ono Pharma, BMS
New P1/2 trial, IO biomarker, Metastases: Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma (clinicaltrials.gov) - May 22, 2015
P1/2, N=25, Not yet recruiting, Sponsor: Rabih Said
- ACT 2001 / Alden Cancer Therapy II
Enrollment open: CryoIT: Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (clinicaltrials.gov) - May 22, 2015
P1, N=20, Recruiting, Sponsor: Alden Cancer Therapy II
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date, Adverse events: Ipilimumab 12-month Intensive Pharmacovigilance Protocol (clinicaltrials.gov) - May 21, 2015
P=N/A, N=6, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Completed | N=30 --> 6 | Initiation date: Dec 2012 --> Feb 2014 | Trial primary completion date: Oct 2015 --> Feb 2015
- | Yervoy (ipilimumab) / BMS
Trial completion, Metastases: Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (clinicaltrials.gov) - May 21, 2015
P2, N=20, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | N=30 --> 6 | Initiation date: Dec 2012 --> Feb 2014 | Trial primary completion date: Oct 2015 --> Feb 2015 Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Enrollment open: Mel62; 6PAC: A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (clinicaltrials.gov) - May 14, 2015
P1/2, N=51, Recruiting, Sponsor: Craig L Slingluff, Jr
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Muphoran (fotemustine) / Servier, Yervoy (ipilimumab) / BMS
Trial completion, Metastases: NIBIT-M1: A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - May 13, 2015
P2, N=86, Completed, Sponsor: Italian Network for Tumor Biotherapy
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (clinicaltrials.gov) - May 7, 2015
P2, N=25, Recruiting, Sponsor: National Center for Tumor Diseases, Heidelberg
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Dec 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker, IO biomarker: NRG-BN002: Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - May 7, 2015
P1, N=42, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Dec 2015 Not yet recruiting --> Suspended
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1 trial, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: OpACIN: Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (clinicaltrials.gov) - May 7, 2015
P1, N=20, Recruiting, Sponsor: The Netherlands Cancer Institute
- |||| Yervoy (ipilimumab) / BMS
Trial completion, Metastases: An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy (clinicaltrials.gov) - May 7, 2015
P2, N=114, Completed, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Suspended Active, not recruiting --> Completed
- || Xpovio (selinexor) / Karyopharm
Enrollment change, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 28, 2015
P1, N=251, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=51 --> 251
- belapectin (GR-MD-02) / Galectin Therap, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 28, 2015
P1, N=22, Recruiting, Sponsor: Providence Health & Services
N=51 --> 251 Trial primary completion date: Mar 2015 --> Mar 2016
- || Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date, Trial primary completion date: YERVOY (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=400, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Mar 2015 --> Mar 2016 Initiation date: Aug 2014 --> Apr 2015 | Trial primary completion date: Sep 2014 --> Oct 2015
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov) - Apr 28, 2015
P2, N=37, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||| Xpovio (selinexor) / Karyopharm
New P1 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 25, 2015
P1, N=251, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Trial primary completion date, Combination therapy, Metastases: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (clinicaltrials.gov) - Apr 22, 2015
P1, N=72, Recruiting, Sponsor: GlaxoSmithKline
Initiation date: Aug 2014 --> Apr 2015 | Trial primary completion date: Sep 2014 --> Oct 2015 Trial primary completion date: Dec 2014 --> Feb 2016
- ACT 2001 / Alden Cancer Therapy II
New P1 trial: CryoIT: Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (clinicaltrials.gov) - Apr 22, 2015
P1, N=20, Not yet recruiting, Sponsor: Alden Cancer Therapy II
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Monotherapy, PD(L)-1 Biomarker: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (clinicaltrials.gov) - Apr 21, 2015
P1, N=412, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2014 --> Feb 2016 Trial primary completion date: Jul 2017 --> Nov 2017
- Yervoy (ipilimumab) / BMS
Enrollment closed: Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (clinicaltrials.gov) - Apr 21, 2015
P2, N=44, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2017 --> Nov 2017 Recruiting --> Active, not recruiting
- ||| Xpovio (selinexor) / Karyopharm
New P1 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 17, 2015
P1, N=51, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center